EndoLogic’s study of their new gastroparesis drug, renzapride, showed no evidence of cardiotoxicity. Renzapride is a 5-HT4 agonist and 5-HT3 antagonist that has been successful in treating the symptoms of gastroparesis, such as abdominal pain, nausea, vomiting, bloating and feelings of fullness. Since the recent study showed no evidence of cardiotoxicity, EndoLogic will be conducting a Phase 2 study of the drug.
What are your thoughts on gastroparesis research? Share your stories, thoughts, and hopes with the Patient Worthy community!